Company intelligence / Profile preview

enGenome

Ownership: Private
Development stage: Commercial

Overview

enGenome’s eVai platform enables precise and early diagnosis of rare diseases with high accuracy in interpreting genomic variants. The technology leverages AI and international guidelines to classify and prioritize pathogenicity of variants, supporting clinical decision-making. VarChat uses generative AI to synthesize information from the literature about genomic variants.

Therapeutic areas: Rare Diseases
Modalities: Software PlatformBioinformatics PlatformAI Software
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on enGenome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enGenome.

Explore the full profile